A European alternative asset management firm sought Marwood’s assistance in evaluating the risks and opportunities associated with a potential investment in a publicly-traded international specialty pharmaceuticals company. The Company manufactures specialty pharmaceutical products, including branded and generic prescriptions, through wholesalers, hospitals and pharmacies in nearly 100 countries around the world. Marwood analyzed the Company’s UK business line specifically.
Marwood concluded that the Company would experience some pricing pressure coming from specific legislative and regulatory changes, however, overall volumes were expected to remain stable. Marwood assessed that though the Company had recently gone under reputational damage, it was mostly among local decision makers who did not have significant direct influence on national purchasing decisions.